AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 January 2023 - 11:00PM
Business Wire
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic
T-cell immunotherapy company, today announced that Diana Brainard,
M.D., Chief Executive Officer, will present at the 41st Annual J.P.
Morgan Healthcare Conference in San Francisco on Tuesday, January
10, 2023, at 2:15 p.m. PST.
A live webcast and archived replay of the presentation will be
available on the Investors & Press section of the AlloVir
website at https://ir.allovir.com.
About AlloVir
AlloVir is a leading late clinical-stage cell therapy company
with a focus on restoring natural immunity against life-threatening
viral diseases in pediatric and adult patients with weakened immune
systems. The company’s innovative and proprietary technology
platforms leverage off-the-shelf, allogeneic, single- and
multi-virus-specific T cells for patients with T cell deficiencies
who are at risk from the life-threatening consequences of viral
diseases. AlloVir’s technology and manufacturing process enable the
potential for the treatment and prevention of a spectrum of
devastating viruses with each single allogeneic cell therapy. The
company is advancing multiple mid- and late-stage clinical trials
across its product portfolio. For more information visit
www.allovir.com or follow us on Twitter or LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230103005155/en/
Media and Investors: Sonia Choi AlloVir
schoi@allovir.com
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From Feb 2024 to Mar 2024
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From Mar 2023 to Mar 2024